Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Johnson and Johnson
Fuji
Federal Trade Commission
Merck
QuintilesIMS
Boehringer Ingelheim
Citi
Covington
Deloitte

Generated: January 19, 2018

DrugPatentWatch Database Preview

NORPRAMIN Drug Profile

« Back to Dashboard

Which patents cover Norpramin, and when can generic versions of Norpramin launch?

Norpramin is a drug marketed by Us Pharm Holdings and is included in one NDA.

The generic ingredient in NORPRAMIN is desipramine hydrochloride. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the desipramine hydrochloride profile page.
Drug patent expirations by year for NORPRAMIN
Pharmacology for NORPRAMIN
Medical Subject Heading (MeSH) Categories for NORPRAMIN

US Patents and Regulatory Information for NORPRAMIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-007 Feb 11, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-006 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NORPRAMIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-006 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-007 Feb 11, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-006 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-007 Feb 11, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
Dow
Moodys
Johnson and Johnson
UBS
Accenture
Deloitte
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot